RENE ALONZO: Open Payments
NPI 1760977425 · GOSHEN, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,306 in 62 payments from 25 companies in 2025. Trend: 2023 $863 · 2024 $1,691 · 2025 $1,306
Food & beverage: $1,287Education: $19
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 13 | $242 |
| Gilead Sciences, Inc. | 2 | $119 |
| Otsuka America Pharmaceutical, Inc. | 5 | $109 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $79 |
| Lundbeck LLC | 3 | $65 |
| AstraZeneca Pharmaceuticals LP | 3 | $54 |
| Axsome Therapeutics, Inc. | 3 | $52 |
| Novo Nordisk Inc | 3 | $51 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $51 |
| Janssen Pharmaceuticals, Inc | 2 | $49 |
Products named: REXULTI, VRAYLAR, Yeztugo, CAPLYTA, UBRELVY, Auvelity, JARDIANCE, SPRAVATO.
Industry payments across IN — which companies pay providers there.
